BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35346999)

  • 21. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Jak/STAT pathway is involved in synaptic plasticity.
    Nicolas CS; Peineau S; Amici M; Csaba Z; Fafouri A; Javalet C; Collett VJ; Hildebrandt L; Seaton G; Choi SL; Sim SE; Bradley C; Lee K; Zhuo M; Kaang BK; Gressens P; Dournaud P; Fitzjohn SM; Bortolotto ZA; Cho K; Collingridge GL
    Neuron; 2012 Jan; 73(2):374-90. PubMed ID: 22284190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
    Tzeng HT; Chyuan IT; Lai JH
    Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends.
    Zhang Y; Gao Z; Jiang F; Yan H; Yang B; He Q; Luo P; Xu Z; Yang X
    Biochem Pharmacol; 2023 Feb; 208():115382. PubMed ID: 36528067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.
    Aparicio-Siegmund S; Sommer J; Monhasery N; Schwanbeck R; Keil E; Finkenstädt D; Pfeffer K; Rose-John S; Scheller J; Garbers C
    Oncotarget; 2014 Apr; 5(8):2131-48. PubMed ID: 24742922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
    Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
    Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
    Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
    Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
    J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type II cGMP‑dependent protein kinase inhibits EGF‑induced JAK/STAT signaling in gastric cancer cells.
    Wu M; Wu Y; Lan T; Jiang L; Qian H; Chen Y
    Mol Med Rep; 2016 Aug; 14(2):1849-56. PubMed ID: 27357186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.
    Huo R; Guo Q; Hu J; Li N; Gao R; Mi L; Zhang Z; Liu H; Guo Z; Zhao H; Zhang L; Xu K
    Drug Des Devel Ther; 2022; 16():991-998. PubMed ID: 35400994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.
    Sabaawy HE; Ryan BM; Khiabanian H; Pine SR
    Carcinogenesis; 2021 Dec; 42(12):1411-1419. PubMed ID: 34415330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
    Shao F; Pang X; Baeg GH
    Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of JAK-STAT Signaling Activation in Hypertrophied Ligamentum Flavum.
    Delen E; Doğanlar O; Delen Ö; Doğanlar ZB; Kılınçer C
    World Neurosurg; 2020 May; 137():e506-e516. PubMed ID: 32059970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
    Bose S; Banerjee S; Mondal A; Chakraborty U; Pumarol J; Croley CR; Bishayee A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32545187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK inhibition and progressive kidney disease.
    Brosius FC; He JC
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):88-95. PubMed ID: 25415616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK-STAT pathway inhibitors in dermatology.
    Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
    An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
    Chapman S; Kwa M; Gold LS; Lim HW
    J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.